Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval Astellas Pharma Inc.

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval Astellas Pharma Inc dapoxetine i norge priligynorge.com . And XenoPort, Inc. today announced that a new drug application offers been filed with the Pharmaceuticals and Medical Device Company in Japan for ASP8825 , known as XP13512 also, as a potential treatment for restless legs syndrome . The info supporting protection and efficacy in the NDA filing comes from the successful Stage 2 research in RLS individuals and long-term safety study conducted by Astellas in Japan and the RLS scientific program conducted by XenoPort in the usa.